NKTR 241220 0.50C (NKTR241220C500) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

NKTR241220C500

Watchlist

0.00
0.000.00%

15min DelayClose Dec 23 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Don't Ignore The Insider Selling In Nektar Therapeutics
Simply Wall StDec 22 08:13 ET
Promising Future for Nektar Therapeutics: Innovative Approach in Autoimmune Disease Treatment With Rezpegaldesleukin
TipRanksDec 12 02:45 ET
Express News | Nektar Therapeutics : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $6.5
ReutersDec 10 06:06 ET
Nektar Therapeutics Announced NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients With Relapsed or Refractory Large B-cell Lymphoma At ASH Meeting; 73% Of NKTR-255 Treatment Group Vs 50% Of Placebo Group...
BenzingaDec 7 15:28 ET
Express News | Nektar Therapeutics Announces Nktr-255 Following Cd19-Directed CAR-T Therapy Enhanced Complete Response Rates in Patients With Relapsed or Refractory Large B-Cell Lymphoma at the 66TH Annual Ash Meeting
ReutersDec 7 12:00 ET
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients With Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
NektarDec 7 00:00 ET

Comments

Teddy123

Dec 10 07:13

Recap: Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual AS

$Nektar Therapeutics (NKTR.US)$
08/12/2024 - 01:00
73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months
NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve (AUC) 0-15 days post-administration being 5.8-fold...

This_Guy

Dec 8 17:28

$Nektar Therapeutics (NKTR.US)$
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
Positive
73% complete response rate at 6 months vs 50% for placebo
5.8-fold improvement in CD8+ CAR-T cell kinetics compared to placebo
Two patients converted from partial to complete response with NKTR-255
Results exceeded historical benchmark data of 41-44% comple...

Trytosaveabit

Dec 8 15:46

Monday watch! PR/updated data released Saturday!

$Nektar Therapeutics (NKTR.US)$ Nektar Therapeutics Announced NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients With Relapsed or Refractory Large B-cell Lymphoma At ASH Meeting; 73% Of NKTR-255 Treatment Group Vs 50% Of Placebo Group Achieved Complete Response At 6 Months
Nektar Therapeutics (NASDAQ:NKTR) today announced results of its Phase 2 proof-of-concept study evaluating NKTR-255 as an adjuvant treatme...

Jaguar8

Nov 18 14:56

NEWS

$Nektar Therapeutics (NKTR.US)$
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
Nektar Therapeutics (NKTR) presented preclinical data for NKTR-422, a novel modified CSF protein, at the 2024 ACR conference. The drug demonstrated promising results in inflammation resolution and tissue repair across multiple preclinical models. NKTR-422functions by targeting anti-inflammatory tissue resident macrop...

Teddy123

Nov 8 17:20

Nektar Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(8.7%)

$Nektar Therapeutics (NKTR.US)$
Target price $7